280 related articles for article (PubMed ID: 16809727)
1. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
Perez EA; Suman VJ; Davidson NE; Martino S; Kaufman PA; Lingle WL; Flynn PJ; Ingle JN; Visscher D; Jenkins RB
J Clin Oncol; 2006 Jul; 24(19):3032-8. PubMed ID: 16809727
[TBL] [Abstract][Full Text] [Related]
2. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
Reddy JC; Reimann JD; Anderson SM; Klein PM
Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
[TBL] [Abstract][Full Text] [Related]
3. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
Dybdal N; Leiberman G; Anderson S; McCune B; Bajamonde A; Cohen RL; Mass RD; Sanders C; Press MF
Breast Cancer Res Treat; 2005 Sep; 93(1):3-11. PubMed ID: 16184453
[TBL] [Abstract][Full Text] [Related]
4. Comparison of HER2 detection methods between central and regional laboratories in Greece.
Papadopoulos S; Kouvatseas G; Skarlos D; Malamos N; Delliou E; Saratsiotou I; Ardavanis A; Mavroudis D; Skarpidi E; Arapantoni P; Karyda I; Patakioyta F; Aravantinos G; Razis E; Fountzilas G; Kosmidis P
Clin Breast Cancer; 2007 Oct; 7(10):784-90. PubMed ID: 18021480
[TBL] [Abstract][Full Text] [Related]
5. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.
Press MF; Sauter G; Bernstein L; Villalobos IE; Mirlacher M; Zhou JY; Wardeh R; Li YT; Guzman R; Ma Y; Sullivan-Halley J; Santiago A; Park JM; Riva A; Slamon DJ
Clin Cancer Res; 2005 Sep; 11(18):6598-607. PubMed ID: 16166438
[TBL] [Abstract][Full Text] [Related]
7. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.
Roche PC; Suman VJ; Jenkins RB; Davidson NE; Martino S; Kaufman PA; Addo FK; Murphy B; Ingle JN; Perez EA
J Natl Cancer Inst; 2002 Jun; 94(11):855-7. PubMed ID: 12048274
[TBL] [Abstract][Full Text] [Related]
8. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
9. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.
Hofmann M; Stoss O; Gaiser T; Kneitz H; Heinmöller P; Gutjahr T; Kaufmann M; Henkel T; Rüschoff J
J Clin Pathol; 2008 Jan; 61(1):89-94. PubMed ID: 17412870
[TBL] [Abstract][Full Text] [Related]
10. HER2 testing in breast cancer: NCCN Task Force report and recommendations.
Carlson RW; Moench SJ; Hammond ME; Perez EA; Burstein HJ; Allred DC; Vogel CL; Goldstein LJ; Somlo G; Gradishar WJ; Hudis CA; Jahanzeb M; Stark A; Wolff AC; Press MF; Winer EP; Paik S; Ljung BM;
J Natl Compr Canc Netw; 2006 Jul; 4 Suppl 3():S1-22; quiz S23-4. PubMed ID: 16813731
[TBL] [Abstract][Full Text] [Related]
11. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
Perez EA; Reinholz MM; Hillman DW; Tenner KS; Schroeder MJ; Davidson NE; Martino S; Sledge GW; Harris LN; Gralow JR; Dueck AC; Ketterling RP; Ingle JN; Lingle WL; Kaufman PA; Visscher DW; Jenkins RB
J Clin Oncol; 2010 Oct; 28(28):4307-15. PubMed ID: 20697084
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).
Perez EA; Press MF; Dueck AC; Jenkins RB; Kim C; Chen B; Villalobos I; Paik S; Buyse M; Wiktor AE; Meyer R; Finnigan M; Zujewski J; Shing M; Stern HM; Lingle WL; Reinholz MM; Slamon DJ
Breast Cancer Res Treat; 2013 Feb; 138(1):99-108. PubMed ID: 23420271
[TBL] [Abstract][Full Text] [Related]
14. Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.
Lee JA; Shaheen M; Walke T; Daly M
Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):325-41. PubMed ID: 21671702
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive value of HER2/neu oncogene in breast cancer.
Masood S; Bui MM
Microsc Res Tech; 2002 Oct; 59(2):102-8. PubMed ID: 12373720
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
17. HER2 testing in breast carcinoma: very low concordance rate between reference and local laboratories in Brazil.
Wludarski SC; Lopes LF; Berto E Silva TR; Carvalho FM; Weiss LM; Bacchi CE
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):112-8. PubMed ID: 20930616
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
[TBL] [Abstract][Full Text] [Related]
19. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.
Baehner FL; Achacoso N; Maddala T; Shak S; Quesenberry CP; Goldstein LC; Gown AM; Habel LA
J Clin Oncol; 2010 Oct; 28(28):4300-6. PubMed ID: 20697093
[TBL] [Abstract][Full Text] [Related]
20. Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases.
Grimm EE; Schmidt RA; Swanson PE; Dintzis SM; Allison KH
Am J Clin Pathol; 2010 Aug; 134(2):284-92. PubMed ID: 20660333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]